Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Tao Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1049-1216; OpenAlex author ID A5063815177. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 11

  1. Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal aden… Co-author DOI 10.1016/j.biomaterials.2025.123630↗
  2. Transcytosis-Triggering Nanoparticles for Overcoming Stromal Barriers and Reversing Immunosuppression in Pancreatic Cancer Combinatorial Therapy. Last author DOI 10.1021/acs.nanolett.4c06372↗
  3. Aminofullerenes as targeted inhibitors of EGFR: from pancreatic cancer inhibitors to Drosophila m. Toxicology. Co-author DOI 10.1080/17435889.2025.2461985↗
  4. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment. Last author DOI 10.1016/j.actbio.2023.05.047↗
  5. Penetrating Micelle for Reversing Immunosuppression and Drug Resistance in Pancreatic Cancer Treatment. Co-author DOI 10.1002/smll.202107712↗
  6. Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2021.121306↗
  7. Smart hypoxia-responsive transformable and charge-reversible nanoparticles for the deep penetration and tumor microenvironment modulation of pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2022.121599↗
  8. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Co-author DOI 10.1016/j.biomaterials.2020.120546↗
  9. Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy. Co-author DOI 10.1039/d0tb00017e↗
  10. Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer. Co-author DOI 10.1021/acs.nanolett.9b00374↗
  11. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. Co-author DOI 10.1002/advs.201701070↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chen Jiang · 8 shared papers, 2019–2026 · strength 1.22
  2. Qinjun Chen · 7 shared papers, 2018–2026 · strength 1.06
  3. Yu Wang · 5 shared papers, 2022–2026 · strength 0.89
  4. Haolin Song · 4 shared papers, 2022–2026 · strength 0.76
  5. Hongrui Fan · 3 shared papers, 2023–2026 · strength 0.64
  6. Yifan Luo · 4 shared papers, 2022–2023 · strength 0.53
  7. Hongyi Chen · 4 shared papers, 2021–2023 · strength 0.50
  8. Shilin Zhang · 2 shared papers, 2023–2025 · strength 0.34
  9. Wenxi Zhou · 3 shared papers, 2019–2022 · strength 0.32
  10. Xinli Chen · 3 shared papers, 2019–2022 · strength 0.32
  11. Qingbing Wang · 2 shared papers, 2020–2022 · strength 0.26
  12. Chufeng Li · 2 shared papers, 2022–2023 · strength 0.26
  13. Yu Zhou · 2 shared papers, 2021–2022 · strength 0.24
  14. Katarzyna Malarz · 1 shared paper, 2025 · strength 0.22
  15. Maciej Serda · 1 shared paper, 2025 · strength 0.22
  16. Chen Liang · 2 shared papers, 2019–2022 · strength 0.20
  17. Xianjun Yu · 2 shared papers, 2019–2022 · strength 0.20
  18. Si Shi · 2 shared papers, 2019–2022 · strength 0.20
  19. Chen Jiang · 2 shared papers, 2018–2021 · strength 0.19
  20. Zhongmin Wang · 1 shared paper, 2020 · strength 0.11
  21. Fuyou Li · 1 shared paper, 2020 · strength 0.11
  22. Wei Huang · 1 shared paper, 2020 · strength 0.11
  23. Xiaoyi Ding · 1 shared paper, 2020 · strength 0.11
  24. Xi He · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.